Positively Aware

Evany Turk and Davina Conner (Pozitively Dee) made a surprise visit to the PA office last week. They talked with editor-in-chief Rick Guasco about why they take part in the magazine’s anti-stigma campaign, what it means to them—and how you can be part of A Day with HIV.

A DAY WITH HIV | Evany Turk, Dee Conner & RIck Guasco A DAY WITH HIV | Evany Turk, Dee Conner & RIck Guasco adaywithhiv.com

Five long-term survivors of HIV—Alfredo Trejo III, PhD, Malcolm Reid, Pollux López, Stewart Nelson-Reid and Toi Washington-Reynolds—join Positively Aware editor-in-chief Rick Guasco to talk about life after diagnosis, confronting stigma, navigating a complex healthcare system and advocating for themselves and their communities. Check out this engaging conversation.

The PA Chat | Long term Survivor Roundtable The PA Chat | HIV Long-term Survivor RoundtableFive long-term sur...

The U.S. Department of Defense (DoD) is reportedly attempting to divert some of the federal funding already approved for clinical research on treatments and vaccines for HIV, influenza, tuberculosis and other infectious diseases, says U.S. Rep. Rosa DeLauro (D-Connecticut). The exact amount of federal funding defense officials are attempting to divert from the National Institutes of Health (NIH) is unknown, but Rep. DeLauro said the amount is in the billions. The agreement to transfer the funds has not been made public.

positivelyaware.com/billions-diverted

Respondents to GLAAD’s survey recognized that HIV stigma exists, but the report found that knowledge of HIV has stagnated or even declined, driven by a lack of reliable information and visibility of HIV in media.
positivelyaware.com/glaad-stigma-report-2026

A few days before BIC-LEN was approved by the FDA, Julene Tripp Weaver talked with Positively Aware about her experience in a clinical trial that helped lead to what is now known as the new medication .

The PA Chat | Julene Tripp Weaver talks about her clinical trial experience on new HIV drug Bixlenvo The PA Chat | Julene Tripp Weaver talks about her clinical trial ex...

Two clinical trial participants—Jeff Taylor and Michael—talk about their experience with the newly FDA-approved HIV drug . It’s a once-daily all-in-one pill that’s a simpler option for heavily treatment-experienced people whose is suppressed, but are on complex, multi-pill regimens. Check out this new installment of “The PA Chat” on Positively Aware’s YouTube channel.

The PA Chat | Jeff Taylor and Michael talk about their experience with new HIV drug Bixlenvo The PA Chat | Jeff Taylor and Michael talk about their experience w...

For people on complex, multi-pill regimens, Bixlenvo could be a once-daily, single-pill option could simplify HIV treatment. “It represents another important step forward in the evolution of two-drug regimens, offering heavily treatment-experienced people with HIV and those on complex ART regimens an opportunity to simplify to a potent two-drug regimen,” says HIV specialist.
positivelyaware.com/bixlenvo-approved

A new study from GLAAD finds only 31% of Gen Z adults feel knowledgeable about HIV. But, “telling young people to just educate themselves means very little if we are not thinking seriously about where that education is coming from,” writes Tymia “Ty” Ballard in a new First Person essay for Positively Aware.
positivelyaware.com/understanding-has-to-catch-up